Ovarian Cancer

Results of the primary analysis of the phase 3b OPINION study supported the use of olaparib maintenance therapy in patients with nongermline BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer.

Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer.

Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.

Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies.

Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy.

Personalized starting doses of niraparib based on body weight and platelet count are associated with reductions in thrombocytopenia and other hematologic events.

When utilized as maintenance therapy after frontline treatment of ovarian cancer in patients with BRCAwt tumors, niraparib improved progression-free survival (PFS), even in the most difficult-to-treat patients.

Results from a previous study indicated that treatment with the combination would lead to improvement in progression-free survival (PFS) compared with treatment with olaparib alone.

Treatment with rucaparib was associated with improvements in progression-free survival, time to first subsequent treatment, and other post-progression efficacy end points.